PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2004 June; 5(2): 60–68.
Published online 2004 April 7. doi:  10.1208/pt050232
PMCID: PMC2750467

Anti-Helicobacter pylori effect of mucoadhesive nanoparticles bearing amoxicillin in experimental gerbils model

Abstract

The purpose of the present study was to design mucoadhesive gliadin nanoparticles (GNP) containing amoxicillin and to evaluate their effectiveness in eradicating Helicobacter pylori. GNP-bearing amoxicillin (AGNP) was prepared by desolvation method. The effect of process variables such as gliadin concentration and initial drug loading on particle size, shape, percent payload, percent entrapment efficiency, in vitro release profile, and mucoadhesive property of GNP was assessed. Rhodamine isothiocyanate-entrapped GNP formulations were prepared to evaluate their in vivo gastric mucoadhesive property in albino rats. With increasing gliadin concentration, the mucoadhesive property of GNP increased. Typically, the maximum amount of nanoparticles remaining was 82±4%, which represented a stronger mucoadhesive propensity and specificity of GNP toward the stomach. In vitro antimicrobial activity of AGNP was evaluated by growth inhibition studies on an isolated H pylori strain. The time required for complete eradication was higher in AGNP than in amoxicillin because of the controlled drug delivery of amoxicillin from AGNP. In vivo clearance of H pylori following oral administration of AGNP to infected Mongolian gerbils was examined. Amoxicillin and AGNP both showed anti-H pylori effects in this experimental model of infection, but the required dose for complete eradication was less in AGNP than in amoxicillin. In conclusion, AGNP eradicated H pylori from the gastrointestinal tract more effectively than amoxicillin because of the prolonged gastrointestinal residence time attributed to mucoadhesion. A dosage form containing mucoadhesive nanoparticles bearing a potential antibiotic should be useful for the complete eradication of H pylori.

Keywords: gliadin, mucoadhesion, nanoparticles, H pylori, amoxicillin

Full Text

The Full Text of this article is available as a PDF (207K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Warren JR, Marshall B. Unified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;321:1273–1275. doi: 10.1016/S0140-6736(83)92719-8. [PubMed] [Cross Ref]
2. Megrand F, Lamouliatte H. Helicobacter pylori and duodenal ulcers. Dig Dis Sci. 1992;37:769–772. doi: 10.1007/BF01296437. [PubMed] [Cross Ref]
3. Forman D, Webb P, Parsonnet J. H. pylori and gastric cancer. Lancet. 1994;343:243–244. doi: 10.1016/S0140-6736(94)91034-0. [PubMed] [Cross Ref]
4. El-Shoura SM. Helicobacter pylori, I: ultrastructural sequences of adherence, attachment, and penetration into the gastric mucosa. Ultrastruct Pathol. 1995;19:323–333. doi: 10.3109/01913129509064237. [PubMed] [Cross Ref]
5. Engstrand L, Graham DY, Scheynius A, Genta RM, El-zaatari F. Is the sanctuary where Helicobacter pylori avoids antibacterial treatment intracellular? Am J Clin Pathol. 1997;108:504–509. [PubMed]
6. Buckholm G, Tannaes T, Nedenskov P, et al. Colony variation of Helicobacter pylori: pathogenic potential is correlated to cell wall lipid composition. Scand J Gastroenterol. 1997;32:445–454. doi: 10.3109/00365529709025079. [PubMed] [Cross Ref]
7. Evans DG, Evans DJ, Graham DY. Adherence and internalization of Helicobacter pylori by HEp-2 cells. Gastroenterology. 1992;102:1557–1567. [PubMed]
8. Kwok T, Backert S, Schwarz H, Berger J, Meyer TF. Specific entry of Helicobacter pylori into cultured gastric epithelial cells via a zipper-like mechanism. Infect Immun. 2002;70:2108–2120. doi: 10.1128/IAI.70.4.2108-2120.2002. [PMC free article] [PubMed] [Cross Ref]
9. Nagahara N, Akiyama Y, Tada M, Nakao M, Kitano M, Ogawa Y. Mucoadhesive microspheres containing amoxycillin for clearance of Helicobacter pylori. Antimicrob Agents Chemother. 1998;42:2492–2494. [PMC free article] [PubMed]
10. Hejazi R, Amiji M. Stomach-specific anti-H. pylori therapy, I: preparation and characterization of tetracycline-loaded chitosan microspheres. Int J Pharm. 2002;235:87–94. doi: 10.1016/S0378-5173(01)00985-1. [PubMed] [Cross Ref]
11. Umamaheshwari RB, Jain S, Jain NK. A new approach in gastroretentive drug delivery system using cholestyramine. Drug Deliv. 2003;10:151–160. doi: 10.1080/713840399. [PubMed] [Cross Ref]
12. Umamaheshwari RB, Jain S, Tripathi PK, Agrawal GP, Jain NK. Floating-bioadhesive microspheres containing acetohydroxamic acid for the clearance of Helicobacter pylori. Drug Deliv. 2002;9:221–233. [PubMed]
13. Ezpeleta I, Irache JM, Stainmesse S, Chabenat C, Popineau Y, Orecchionic AM. Preparation of Ulex europaeus lectin-gliadin nanoparticles conjugates and their interaction with gastrointestinal mucus. Int J Pharm. 1999;191:25–32. doi: 10.1016/S0378-5173(99)00232-X. [PubMed] [Cross Ref]
14. Arangoa MA, Campanero MA, Renedo MJ, Ponchel G, Irache JM. Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics. Pharm Res. 2001;18:1521–1527. doi: 10.1023/A:1013018111829. [PubMed] [Cross Ref]
15. Arangoa MA, Ponchel G, Orecchioni AM, Renedo MJ, Duchene D, Irache JM. Bioadhesive potential of gliadin nanoparticulate systems. Eur J Pharm Sci. 2000;11:333–341. doi: 10.1016/S0928-0987(00)00121-4. [PubMed] [Cross Ref]
16. Fontana G, Licciardi M, Mansueto S, Schilaci S, Giammona G. Amoxycillin-loaded polyethylcyanoacrylate nanoparticles: influence of PEG coating on the particle size, drug release rate and phagocytic uptake. Biomaterials. 2001;22:2857–2865. doi: 10.1016/S0142-9612(01)00030-8. [PubMed] [Cross Ref]
17. Arangoa MA, Campanero MA, Popineau Y, Hirai S, Toguchi H. Evaluation and characterization of gliadin nanoparticles and isolates by reversed phase HPLC. J Cereal Sci. 2000;31:223–228. doi: 10.1006/jcrs.1999.0299. [Cross Ref]
18. Wang J, Tauch Y, Deguchi Y, Morimoto K, Tabata Y, Ikada Y. Positively charged gelatin microspheres as gastric mucoadhesive drug delivery system for clearance of H. pylori. Drug Deliv. 2000;7:237–243. doi: 10.1080/107175400455173. [PubMed] [Cross Ref]
19. Akiyama Y, Nagahara N, Tashihara T, Morimoto K, Tabata Y, Ikada Y. In vitro and in vivo evaluation of mucoadhesive microspheres prepared for the gastrointestinal tract using polyglycerol esters of fatty acids and a poly(acrylic acid) derivative. Pharm Res. 1995;12:397–405. doi: 10.1023/A:1016208703380. [PubMed] [Cross Ref]
20. Ikeno T, Ota H, Sngiyama A. Helicobacter pylori-induced chronic active gastritis, intestinal metaplasia and gastric ulcer in Mongolian gerbils. Am J Pathol. 1999;154:951–960. [PubMed]
21. Shah S, Qaqish R, Patel V, Amiji M. Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for Helicobacter pylori infection. J Pharm Pharmacol. 1999;51:667–672. doi: 10.1211/0022357991772952. [PubMed] [Cross Ref]
22. Berry V, Jennings K, Woodnutt G. Bactericidal and morphological effects of amoxycillin on Helicobacter pylori. Antimicrob Agents Chemother. 1995;39:1859–1861. [PMC free article] [PubMed]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists